Methods and pharmaceutical compositions for the treatment of

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. In particular, the […]

Pharmaceutical compositions for use in the treatment of brain injuries

The invention is in the field of neuroregenerative medicine. Controlling the fate of neural stem cells represents a key therapeutic strategy in […]

Inhibition of usp14 impairs melanoma cell survival and overcomes

The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 […]

Slitrk6 as a target for cancers associated with activation of the mapk

The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the […]

Increasing tfr1 palmitoylation as a novel therapeutic strategy for

The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration with brain iron accumulation (NBIA). […]

A microrna switch regulates the rise in hypothalamic gnrh production

A method for diagnosing a reproduction-related disorder in an individual, comprising:a) measuring the level of a miR200 nucleic acid and/or miR155 […]

Modulator of wip1 levels to treat wolfram syndrome

The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The […]

Method for the treatment of disease associated with angiogenesis

The present invention relates to a method of treating disease associated with angiogenesis using an N-Methyl-D-aspartate receptor (NMDA) antagonist. […]

Vdac1 inhibition for the treatment of peripheral demyelination

Here the inventors show, using in vivo imaging and viral approaches, that calcium released by mitochondrial VDAC1 directly induces Schwann cell […]

Protease nexin-1 inhibitor for the treatment of haemorrhagic disease

The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 […]